{"id":9641,"date":"2017-06-13T14:39:15","date_gmt":"2017-06-13T14:39:15","guid":{"rendered":"http:\/\/www.fetaldna.it\/metodologia-inipt\/"},"modified":"2022-03-15T21:51:49","modified_gmt":"2022-03-15T21:51:49","slug":"nipt-metodologia-inipt","status":"publish","type":"page","link":"https:\/\/www.fetaldna.it\/fr\/nipt-metodologia-inipt\/","title":{"rendered":"FETALDNA INIPT"},"content":{"rendered":"

[vc_row full_width=”stretch_row” content_placement=”middle” css=”.vc_custom_1642093547936{padding-top: 100px !important;padding-bottom: 50px !important;background-image: url(https:\/\/www.fetaldna.it\/wp-content\/uploads\/2022\/01\/Header_inipt.png?id=13439) !important;background-position: center !important;background-repeat: no-repeat !important;background-size: cover !important;}”][vc_column css=”.vc_custom_1642010227194{padding-top: 100px !important;padding-bottom: 100px !important;}”][\/vc_column][\/vc_row][vc_row 0=”” softing_row_prepad=”ptb-30″][vc_column 0=””][vc_custom_heading text=”Du NIPT \u00e0 l’iNIPT : innovation dans le screening pr\u00e9natal” font_container=”tag:h2|text_align:center” use_theme_fonts=”yes”][vc_column_text]<\/p>\n

Au-del\u00e0 du s\u00e9quen\u00e7age massif parall\u00e8le, le s\u00e9quen\u00e7age massif parall\u00e8le et num\u00e9rique est d\u00e9sormais \u00e0 la pointe de la technologie.<\/h3>\n

[\/vc_column_text][vc_column_text css=”.vc_custom_1647380435226{padding-top: 3% !important;}”]La technologie qui rend FetalDNA unique dans le paysage des tests d’ADN f\u0153tal est iNIPTTM<\/sup>, d\u00e9velopp\u00e9e au sein du laboratoire de g\u00e9n\u00e9tique de l\u2019Altamedica Healthcare Center \u00e0 Rome.<\/p>\n

Il s’agit d’une plateforme int\u00e9gr\u00e9e de s\u00e9quen\u00e7age g\u00e9n\u00e9tique de derni\u00e8re g\u00e9n\u00e9ration<\/strong>, qui implique l’utilisation synergique des technologies de s\u00e9quen\u00e7age massif d’ADN (Next Generation Sequencing) et Digital PCR (Polymerase Chain Reaction).<\/p>\n

Alors que la m\u00e9thode d\u00e9j\u00e0 connue de s\u00e9quen\u00e7age massif parall\u00e8le permet l’analyse de l’ensemble du g\u00e9nome, la PCR num\u00e9rique repr\u00e9sente la possibilit\u00e9 d’investiguer des mutations et des anomalies g\u00e9n\u00e9tiques avec une sensibilit\u00e9 et une fiabilit\u00e9 jamais atteintes auparavant.<\/p>\n

De plus, l’utilisation d’analyses bioinformatiques exclusives offre une tr\u00e8s grande fiabilit\u00e9 des r\u00e9sultats<\/strong>.[\/vc_column_text][\/vc_column][\/vc_row][vc_row 0=””][vc_column 0=””][vc_column_text]<\/p>\n

Sup\u00e9riorit\u00e9 de l’iNIPTTM sur le NIPT traditionnel : preuves scientifiques<\/h3>\n

[\/vc_column_text][vc_column_text css=”.vc_custom_1647380546230{padding-top: 3% !important;}”]Il convient de noter qu’au-del\u00e0 des taux de r\u00e9ussite excessifs d\u00e9clar\u00e9s par les tests NIPT traditionnels sur le march\u00e9 depuis des ann\u00e9es, leur validit\u00e9 r\u00e9elle ne peut \u00eatre \u00e9tablie que par Amniocent\u00e8se \/ CVS.<\/p>\n

Au cours de la p\u00e9riode de septembre 2014 \u00e0 septembre 2017, le Centre Altamedica de Rome a enregistr\u00e9 15 173<\/strong> proc\u00e9dures pr\u00e9natales invasives li\u00e9es \u00e0 l’amniocent\u00e8se<\/strong> et au CVS<\/strong>.<\/p>\n

Dans ce grand groupe, nous avons s\u00e9lectionn\u00e9 385 grossesses<\/strong> dans lesquelles un test NIPT a rapport\u00e9 un doute sur une anomalie chromosomique ou sous-chromosomique ou des \u00e9chographies ont r\u00e9v\u00e9l\u00e9 la suspicion d’une anomalie chromosomique ou g\u00e9n\u00e9tique m\u00eame si le test NIPT \u00e9tait n\u00e9gatif pour la pathologie chromosomique.<\/p>\n

Cette \u00e9tude pr\u00e9clinique a montr\u00e9 que:[\/vc_column_text][\/vc_column][\/vc_row][vc_row full_width=”stretch_row” equal_height=”yes” content_placement=”middle” softing_row_prepad=”ptb-30″ css=”.vc_custom_1642091380162{background-color: #f2483e !important;}”][vc_column][vc_row_inner content_placement=”middle”][vc_column_inner width=”1\/2″ css=”.vc_custom_1642091516293{border-top-width: 2px !important;border-right-width: 2px !important;border-bottom-width: 2px !important;border-left-width: 2px !important;padding-top: 3% !important;padding-right: 3% !important;padding-bottom: 3% !important;padding-left: 3% !important;background-color: #ffffff !important;border-left-color: #f2483e !important;border-left-style: solid !important;border-right-color: #f2483e !important;border-right-style: solid !important;border-top-color: #f2483e !important;border-top-style: solid !important;border-bottom-color: #f2483e !important;border-bottom-style: solid !important;border-radius: 5px !important;}”][vc_column_text]Le premier groupe<\/strong> a rapport\u00e9 197 femmes<\/strong> avec un test NIPT positif<\/strong> qui ont subi un examen pr\u00e9natal invasif (amniocent\u00e8se ou CVS) pour confirmer le diagnostic (TAB 1<\/strong><\/a>).[\/vc_column_text][vc_single_image image=”10809″ img_size=”large” alignment=”center”][vc_column_text]<\/p>\n

Les faux positifs vont de 10% \u00e0 84% (pour les microd\u00e9l\u00e9tions), 9,5% pour T21 et 36,8% pour T18, la dPCR r\u00e9duit \u00e0 z\u00e9ro le taux de faux positifs<\/strong> pour les anomalies f\u0153tales des chromosomes 18 et 21.<\/p>\n

L’\u00e9quipe d’Altamedica a r\u00e9alis\u00e9 le test FetalDNA en pr\u00e9clinique | Technologie iNIPT™ pour valider sa pr\u00e9cision par rapport au NIPT traditionnel.<\/strong>[\/vc_column_text][\/vc_column_inner][vc_column_inner width=”1\/2″ css=”.vc_custom_1642091525232{border-top-width: 2px !important;border-right-width: 2px !important;border-bottom-width: 2px !important;border-left-width: 2px !important;padding-top: 3% !important;padding-right: 3% !important;padding-bottom: 3% !important;padding-left: 3% !important;background-color: #ffffff !important;border-left-color: #f2483e !important;border-left-style: solid !important;border-right-color: #f2483e !important;border-right-style: solid !important;border-top-color: #f2483e !important;border-top-style: solid !important;border-bottom-color: #f2483e !important;border-bottom-style: solid !important;border-radius: 5px !important;}”][vc_column_text]Le deuxi\u00e8me groupe<\/strong> comprenait 188 femmes<\/strong> ayant subi un diagnostic pr\u00e9natal invasif apr\u00e8s un test NIPT n\u00e9gatif mais avec une suspicion \u00e9chographique de pathologie chromosomique f\u0153tale (TAB 2<\/strong><\/a>).[\/vc_column_text][vc_single_image image=”11143″ img_size=”large” alignment=”center”][vc_column_text]<\/p>\n

Les faux n\u00e9gatifs vont de 5 % \u00e0 10 %, la dPCR r\u00e9duit \u00e0 z\u00e9ro le taux de faux n\u00e9gatifs<\/strong> pour les anomalies f\u0153tales des chromosomes 18 et 21.<\/p>\n

L’\u00e9quipe d’Altamedica a ex\u00e9cut\u00e9 le test FetalDNA | technologie iNIPT™ en pr\u00e9clinique afin de valider sa pr\u00e9cision par rapport au NIPT traditionnel.<\/strong>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row][vc_row el_id=”tab2″][vc_column][vc_column_text]* Ultrasound Obstet Gynecol. 2017 Jun; 49(6):815-816. doi: 10.1002\/uog.17483.\u00a0<\/i>ISUOG updated consensus statement on the impact of cfDNA aneuploidy testing<\/i> on screening policies and prenatal ultrasound practice.\u00a0<\/i>S<\/i>alomon LJ, Alfirevic Z, Audibert F, Kagan KO, Paladini D, Yeo G, <\/i>Raine-Fenning N; ISUOG Clinical Standards Committee.\u00a0<\/i>[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

[vc_row full_width=”stretch_row” content_placement=”middle” css=”.vc_custom_1642093547936{padding-top: 100px !important;padding-bottom: 50px !important;background-image: url(https:\/\/www.fetaldna.it\/wp-content\/uploads\/2022\/01\/Header_inipt.png?id=13439) !important;background-position: center !important;background-repeat: no-repeat !important;background-size: cover !important;}”][vc_column css=”.vc_custom_1642010227194{padding-top: 100px !important;padding-bottom: 100px !important;}”][\/vc_column][\/vc_row][vc_row 0=”” softing_row_prepad=”ptb-30″][vc_column 0=””][vc_custom_heading text=”Du NIPT \u00e0 l’iNIPT : innovation dans le screening pr\u00e9natal” font_container=”tag:h2|text_align:center” use_theme_fonts=”yes”][vc_column_text] Au-del\u00e0 du s\u00e9quen\u00e7age massif parall\u00e8le, le s\u00e9quen\u00e7age massif parall\u00e8le et num\u00e9rique est d\u00e9sormais \u00e0 la pointe de la technologie….<\/p>\n","protected":false},"author":3,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"custom-page.php","meta":{"footnotes":""},"class_list":["post-9641","page","type-page","status-publish","hentry"," c-blog-1-item nt-post-class"],"yoast_head":"\nNIPT - metodologia innovativa iNIPT per screening prenatale - FetalDNA<\/title>\n<meta name=\"description\" content=\"La metodologia iNIPT supera la NIPT tradizionale, integrando il Sequenziamento massivo del DNA (NGS) con la Digital PCR. Brevetto Altamedica\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.fetaldna.it\/fr\/nipt-metodologia-inipt\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NIPT - metodologia innovativa iNIPT per screening prenatale - FetalDNA\" \/>\n<meta property=\"og:description\" content=\"La metodologia iNIPT supera la NIPT tradizionale, integrando il Sequenziamento massivo del DNA (NGS) con la Digital PCR. Brevetto Altamedica\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.fetaldna.it\/fr\/nipt-metodologia-inipt\/\" \/>\n<meta property=\"og:site_name\" content=\"FetalDNA\" \/>\n<meta property=\"article:modified_time\" content=\"2022-03-15T21:51:49+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.fetaldna.it\\\/fr\\\/nipt-metodologia-inipt\\\/\",\"url\":\"https:\\\/\\\/www.fetaldna.it\\\/fr\\\/nipt-metodologia-inipt\\\/\",\"name\":\"NIPT - metodologia innovativa iNIPT per screening prenatale - FetalDNA\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.fetaldna.it\\\/#website\"},\"datePublished\":\"2017-06-13T14:39:15+00:00\",\"dateModified\":\"2022-03-15T21:51:49+00:00\",\"description\":\"La metodologia iNIPT supera la NIPT tradizionale, integrando il Sequenziamento massivo del DNA (NGS) con la Digital PCR. Brevetto Altamedica\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.fetaldna.it\\\/fr\\\/nipt-metodologia-inipt\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.fetaldna.it\\\/fr\\\/nipt-metodologia-inipt\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.fetaldna.it\\\/fr\\\/nipt-metodologia-inipt\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.fetaldna.it\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FETALDNA INIPT\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.fetaldna.it\\\/#website\",\"url\":\"https:\\\/\\\/www.fetaldna.it\\\/\",\"name\":\"FetalDNA | Il test prenatale su DNA fetale\",\"description\":\"Il test prenatale di ultima generazione\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.fetaldna.it\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NIPT - metodologia innovativa iNIPT per screening prenatale - FetalDNA","description":"La metodologia iNIPT supera la NIPT tradizionale, integrando il Sequenziamento massivo del DNA (NGS) con la Digital PCR. Brevetto Altamedica","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.fetaldna.it\/fr\/nipt-metodologia-inipt\/","og_locale":"fr_FR","og_type":"article","og_title":"NIPT - metodologia innovativa iNIPT per screening prenatale - FetalDNA","og_description":"La metodologia iNIPT supera la NIPT tradizionale, integrando il Sequenziamento massivo del DNA (NGS) con la Digital PCR. Brevetto Altamedica","og_url":"https:\/\/www.fetaldna.it\/fr\/nipt-metodologia-inipt\/","og_site_name":"FetalDNA","article_modified_time":"2022-03-15T21:51:49+00:00","twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.fetaldna.it\/fr\/nipt-metodologia-inipt\/","url":"https:\/\/www.fetaldna.it\/fr\/nipt-metodologia-inipt\/","name":"NIPT - metodologia innovativa iNIPT per screening prenatale - FetalDNA","isPartOf":{"@id":"https:\/\/www.fetaldna.it\/#website"},"datePublished":"2017-06-13T14:39:15+00:00","dateModified":"2022-03-15T21:51:49+00:00","description":"La metodologia iNIPT supera la NIPT tradizionale, integrando il Sequenziamento massivo del DNA (NGS) con la Digital PCR. Brevetto Altamedica","breadcrumb":{"@id":"https:\/\/www.fetaldna.it\/fr\/nipt-metodologia-inipt\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.fetaldna.it\/fr\/nipt-metodologia-inipt\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.fetaldna.it\/fr\/nipt-metodologia-inipt\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.fetaldna.it\/fr\/"},{"@type":"ListItem","position":2,"name":"FETALDNA INIPT"}]},{"@type":"WebSite","@id":"https:\/\/www.fetaldna.it\/#website","url":"https:\/\/www.fetaldna.it\/","name":"FetalDNA | Il test prenatale su DNA fetale","description":"Il test prenatale di ultima generazione","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.fetaldna.it\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"}]}},"_links":{"self":[{"href":"https:\/\/www.fetaldna.it\/fr\/wp-json\/wp\/v2\/pages\/9641","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fetaldna.it\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.fetaldna.it\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.fetaldna.it\/fr\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fetaldna.it\/fr\/wp-json\/wp\/v2\/comments?post=9641"}],"version-history":[{"count":3,"href":"https:\/\/www.fetaldna.it\/fr\/wp-json\/wp\/v2\/pages\/9641\/revisions"}],"predecessor-version":[{"id":14082,"href":"https:\/\/www.fetaldna.it\/fr\/wp-json\/wp\/v2\/pages\/9641\/revisions\/14082"}],"wp:attachment":[{"href":"https:\/\/www.fetaldna.it\/fr\/wp-json\/wp\/v2\/media?parent=9641"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}